2021: The Year of Advances in Unresectable HCC?

Amit Singal, MD, MS, reviews challenges in the management of advanced hepatocellular carcinoma (HCC).

Amit Singal, MD, MS, and Masatoshi Kudo, MD, PhD, discuss the benefit/risk ratio of first-line locoregional therapies in advanced hepatocellular carcinoma.

Examining individual patient assessment for using TACE (transarterial chemoembolization) in unresectable BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma and the health care team involved.

Practical considerations for TACE (transarterial chemoembolization) in unresectable BCLC stage B HCC, including assessing radiologic response and determining when to initiate systemic therapy.

Assessing outcomes associated with systemic therapy, such as lenvatinib and sorafenib, for patients with BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma based on data from the IMbrave150 and GIDEON trials.

Amit Singal, MD, MS, and Masatoshi Kudo, MD, PhD, review the REFLECT trial and discuss the use of lenvatinib in patients with BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma.

Amit Singal, MD, MS, and Masatoshi Kudo, MD, PhD, comment on the role of TACE (transarterial chemoembolization) in early line settings for the management of BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma and whether systemic therapy has the potential to replace TACE.

Masatoshi Kudo, MD, PhD, reviews data from the LEAP-012 and TACTICS trials for intermediate stage hepatocellular carcinoma.

Stephen L. Chan, MD, reviews data from key trials of emerging combinations of TACE (transarterial chemoembolization), plus systemic therapies for BCLC (Barcelona Clinic Liver Cancer) stage B or C hepatocellular carcinoma.

Amit Singal, MD, MS, and Stephen L. Chan, MD, review the IMbrave150, LEAP-002, and CheckMate 9DW trials for unresectable hepatocellular carcinoma.

A review of currently available ongoing data for unresectable HCC (hepatocellular carcinoma), including data from the HIMALAYA trial.

Amit Singal, MD, shares his thoughts on approaching second-line therapy for HCC (hepatocellular carcinoma) after first-line atezolizumab-bevacizumab as well as options for patients with Child-Pugh B disease who are ineligible for frontline atezolizumab-bevacizumab.

Considerations for selecting a VEGF TKI (tyrosine kinase inhibitor) in the second-line setting for the management of HCC (hepatocellular carcinoma).

Amit Singal, MD, comments on the use of cabozantinib in patients with Child-Pugh A and Child-Pugh B disease as well as regorafenib in advanced stage HCC (hepatocellular carcinoma).

Amit Singal, MD; Masatoshi Kudo, MD, PhD; and Stephen L. Chan, MD, share their personal approaches to sequencing with an anti-PD-1 antibody after first-line atezolizumab-bevacizumab in HCC (hepatocellular carcinoma).

Stephen L. Chan, MD, comments on the use of AFP as a predictive biomarker in HCC (hepatocellular carcinoma) and the current use of ramucirumab.

Stephen L. Chan, MD; Masatoshi Kudo, MD, PhD; and Amit Singal, MD, discuss the future treatment landscape for the management of HCC (hepatocellular carcinoma).